Generated by All in One SEO Pro v4.9.0, this is an llms.txt file, used by LLMs to index the site.

# Bora Pharmaceuticals Premium CDMO

## Posts

- [Form testing](http://boracorpcdmo.com/form-testing/)
- [entesting](http://boracorpcdmo.com/entesting/)
- [Friendshoring: A Strategic Shift in Pharma Supply Chains ](http://boracorpcdmo.com/friendshoring-a-strategic-shift-in-pharma-supply-chains/) - The pharmaceutical industry has faced unprecedented challenges in recent years. The global pandemic was, we thought, a ‘once in a hundred years’ event, but that has been followed by a series of global conflicts and multiple geopolitical tensions that have exposed vulnerabilities in drug supply chains, leading to shortages and other disruptions. To ensure a How optimizing equipment maintenance and management strategies increase reliability and reduce operating costs.
- [Solving Controlled Release Drug Delivery Challenges Using Extrusion-Spheronization](http://boracorpcdmo.com/solving-controlled-release-drug-delivery-challenges-using-extrusion-spheronization/) - Extrusion Spheronization’s Expanding Influence as a Drug Manufacturing Driver Widely acknowledged as a predictable vehicle for the control, distribution and transportation of therapeutic agents around the body, E-S engineered formulations make a variety of common and emerging controlled release dose forms possible. These include fixed-dose combinations (FDCs), combined, modified release single-capsule forms and emerging
- [eBook - Redefining scalability: Strategies for enhancing early drug development to future-proof later stages](http://boracorpcdmo.com/ebook-redefining-scalability-strategies-for-enhancing-early-drug-development-to-future-proof-later-stages/) - Meeting the rising demand for biologics Biologics have revolutionized the medical landscape with their targeted mechanisms of action and potential for treating a wide array of indications. As the global population grapples with an increasing burden of disease, including cancer and chronic conditions, he demand for effective biologics has surged, propelling the biopharmaceutical industry into How optimizing equipment maintenance and management strategies increase reliability and reduce operating costs.
- [eBook - Addressing the complex demands of cell line development](http://boracorpcdmo.com/ebook-addressing-the-complex-demands-of-cell-line-development/) - How can Bora Biologics help to support your next biologics project? Having a robust Cell Line Development (CLD) strategy is the foundation of biologic production that can propel a project, helping to streamline production while mitigating risk. A tailored and optimized cell line can be instrumental in overcoming development and manufacturing challenges and achieving a How optimizing equipment maintenance and management strategies increase reliability and reduce operating costs.
- [Bora Appoints J.D. Mowery As First Division President Of Its CDMO Business](http://boracorpcdmo.com/bora-appoints-j-d-mowery-as-first-division-president-of-its-cdmo-business/) - Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), a global leader in pharmaceutical manufacturing, today announced the appointment of J.D. Mowery to the newly created position of Division President of Bora’s CDMO business. “Through our acquisitions and joint venture with Tanvex we have added four U.S. sites to our network this year, and
- [Bora Company Presentation at 43rd Annual J.P. Morgan Healthcare Conference](http://boracorpcdmo.com/bora-company-presentation-at-43rd-annual-j-p-morgan-healthcare-conference-2/) - 43rd Annual J.P. Morgan Healthcare Conference Bora Pharmaceuticals has been invited to participate in the prestigious J.P. Morgan Healthcare Conference and will be hosting a company presentation on January 16, 2025, at 2:15pm PST. We invite you to join us at the session via the link below to hear the insights shared by Bora Chairman
- [Bora Health Partners with National Taiwan University Hospital andPatient Groups to Raise Awareness on World Parkinson’s Day](http://boracorpcdmo.com/bora-health-partners-with-national-taiwan-university-hospital-andpatient-groups-to-raise-awareness-on-world-parkinsons-day/) - April 11 is World Parkinson’s Day. To mark the occasion, the Center for Parkinson and Movement Disorders at National Taiwan University Hospital (NTUH), the Taiwan Parkinson’s Disease Association, and Bora Health jointly organized a public event titled “Move Your Body and Mind: A Collaborative Treasure Hunt for World Parkinson’s Day.” Nearly a hundred patients, accompanied
- [Bora Wins Prestigious CDMO Leadership Awards](http://boracorpcdmo.com/bora-wins-prestigious-cdmo-leadership-awards/) - Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), a global leader in pharmaceutical manufacturing, today celebrated winning three Outsourced Pharma Leadership Awards: Best New or Transformed CDMO, Biologics - Global, and Small Molecule Dosage Form - Global. The awards were presented at a ceremony at The POOL in mid-town Manhattan, New York City,
- [Bora Secures FDA Approval for CDMO Services](http://boracorpcdmo.com/bora-secures-fda-approval-for-cdmo-services/) - Successful FDA general inspection for its facility in Zhunan, Taiwan Bora, a contract development and manufacturing organization (CDMO) that specializes in modified release (MR) and solvent production, has reported a successful FDA general inspection for its facility in Zhunan, Taiwan. The publicly listed company recently hosted the site’s fifth successful inspection by the
- [Demand for specialist expertise in formulation development and compound manufacturing is continuing to rise](http://boracorpcdmo.com/demand-for-specialist-expertise-in-formulation-development-and-compound-manufacturing-is-continuing-to-rise/) - Pharmaceuticals are shifting towards developing modified release dosage forms In line with this, the pharmaceutical industry is seeing a shift to develop modified release dosage forms that can deliver more therapeutic value and better outcomes for different groups, such as pediatric and geriatric patients. Bora's Business Development Department spoke to Pharmaceutical Technology Europe
- [Fast-growing CDMO Opens U.S. Office](http://boracorpcdmo.com/fast-growing-cdmo-opens-u-s-office/) - Bora, a contract development and manufacturing organization (CDMO) that specializes in complex modified release (MR) products and solvent production, has announced the opening of its first North American office in Delaware, U.S. The Asia-Pacific (APAC)-headquartered CDMO, which has invested over $60 million in acquiring world class facilities in recent years, has established the
- [Bora Pharmaceuticals to acquire GSK Mississauga-based Facility](http://boracorpcdmo.com/bora-pharmaceuticals-to-acquire-gsk-mississauga-based-facility/) - Skilled manufacturing staff to be retained as site becomes Bora Pharmaceuticals' flagship North American facility Bora Pharmaceuticals Co., Ltd (6472.TWO) and GSK announced today they have entered into an agreement under which Bora Pharmaceuticals will acquire GSK's Mississauga, Ontario (Canada) facility. The GSK facility produces approximately 50 different products for over 100 markets
- [Bora's Responsibility to Navigate COVID-19](http://boracorpcdmo.com/boras-responsibility-to-navigate-covid-19/) - A message from Bora’s CEO Bobby Sheng A letter to our partners, customers, and all stakeholders: As the world is fighting to contain the COVID-19 (the coronavirus), I wanted to reach out and provide an update on the actions that Bora is taking to prevent the spread of the virus, ensure business continuity, and support
- [Introducing Bora’s New Drug Strategy and Development Blog Series](http://boracorpcdmo.com/introducing-boras-new-drug-strategy-and-development-blog-series/) - Welcome to 'BoraSphere' In these unique times, the call for education and dialogue within the Pharma Community and its contract manufacturing partners has never been more apparent or necessary. Pharma’s vital role can hardly be understated during the COVID-19 pandemic and the role that their contract manufacturing partners play in providing much needed drugs. It’s
- [Pharmaceutical Technology "Securing the Supply Chain"](http://boracorpcdmo.com/pharmaceutical-technology-securing-the-supply-chain/) - The global COVID-19 pandemic has highlighted the need for the pharmaceutical industry to strengthen its supply chain. June 2, 2020 Volume 44, Issue 6 Page Number: 38–40 By Felicity Thomas, Pharmaceutical Technology The global population is aging, the prevalence of chronic conditions is rising, and medicines are becoming more widely accessible globally, which are all
- [How to Control and Modify the Release of Today’s Insoluble, Potent API's](http://boracorpcdmo.com/how-to-control-and-modify-the-release-of-todays-insoluble-potent-apis/) - Synchronizing and controlling API delivery, extrusion-spheronization is a robust technique offers pharmaceutical companies a reliable, efficient way to modify and control the release of many of today's insoluble drug compounds and manufacture the most effective patient-centric therapeutics. Manufacturing spherical oral solid dose beads via extrusion-spheronization is a well-understood technology perfect for controlling and modifying the
- [How Extrusion-Spheronization Can Help to Control Delivery and Enhance Performance of Complex Therapies](http://boracorpcdmo.com/how-extrusion-spheronization-can-help-to-control-delivery-and-enhance-performance-of-complex-therapies/) - In this blog, we explore why and how the technique of extrusion-spheronization offers pharmaceutical companies a robust, proven way to manufacture today’s most complex therapies. We also discuss the key considerations for drug developers who are looking to select a contract manufacturer as a partner to deliver this technique. The Right Choice for Encapsulated Solid
- [Interview of Bobby Sheng, CEO of Bora, by "Molecule to Market"](http://boracorpcdmo.com/interview-of-bobby-sheng-ceo-of-bora-by-molecule-to-market/) - The Podcast, "Molecule to Market" features Bobby Sheng Listen to podcast In this episode of the podcast - "Molecule to Market," you’ll go inside the outsourcing space of the global drug development sector with Bobby Sheng, CEO and Chairman of Bora Pharmaceuticals. A California native and an experienced leader in the pharmaceutical industry,
- [Bora’s CEO, Bobby Sheng’s interview with The Medicine Maker magazine](http://boracorpcdmo.com/boras-ceo-bobby-shengs-interview-with-the-medicine-maker-magazine/) - Sitting Down with Bobby Sheng, Chairman and CEO of Bora Pharmaceuticals, Taiwan The Medicine Maker's Interview with Bobby Sheng by James Strachan | 07/22/2020 | Link to the Interview Did you always want to work in pharma? My upbringing was a little unusual in that my father owned a pharmaceutical company in Taiwan.
- [How Can You Get Two or Three API's to Play Nice In One Capsule?](http://boracorpcdmo.com/how-can-you-get-two-or-three-apis-to-play-nice-in-one-capsule/) - Multiple-unit pellet system (MUPS) can offer a solution to complex dose control Oral solid dose (OSD) delivery remains the most popular route for administering drugs. Market forces are prompting pharmaceutical companies to pursue a broad array of OSD development strategies to make their active pharmaceutical ingredients (APIs) and formulations therapeutically effective and patient friendly. One
- [Pharmaceutical Technology "Opening the Door to Successful Drug Development"](http://boracorpcdmo.com/pharmaceutical-technology-opening-the-door-to-successful-drug-development/) - The right outsourcing partner should open up access to expertise and technical capabilities in a broad range of dosage forms to ensure commercial success. August 1, 2020Volume 2020 Supplement, Issue 3Page Number: s6-s9By Felicity Thomas, Pharmaceutical Technology As the need for innovation in drug development is increasing, so too is the requirement for companies
- [How to Minimize Production Downtime by Maintaining Your Tablet Compression Tooling](http://boracorpcdmo.com/how-to-minimize-production-downtime-by-maintaining-your-tablet-compression-tooling/) - We here at Bora are often asked by our clients what the best approach to maintaining tablet compression tooling to maximize the life of the tooling and optimize performance during production so that downtime can be minimized. Optimizing and maintaining tablet compression tooling surely brings challenges. Poorly performing tools are a challenge all pharmaceutical manufacturers
- [What is the Status of Drug Intellectual Property (IP) in Taiwan?](http://boracorpcdmo.com/what-is-the-status-of-drug-intellectual-property-ip-in-taiwan/) - One of the biggest concerns about working in Asia by North American drug companies is the sanctity of their Intellectual Property (IP). Will it be copied and then all the hard work, years of time and money invested lost? These are valid concerns! Taiwan, officially known as the Republic of China (ROC), is an
- [Benefits of Converting Waste Heat to Create Sustainable Steam Systems in Your Pharmaceutical Manufacturing Plant](http://boracorpcdmo.com/benefits-of-converting-waste-heat-to-create-sustainable-steam-systems-in-your-pharmaceutical-manufacturing-plant/) - Bora Pharmaceuticals has come up with a way to benefit our Zhunan site by converting the waste heat generated from our steam system. To support operations running smoothly at the Bora Zhunan site, the boiler needs to generate 1225 kg of steam per hour to fulfill the facility’s requirements. When steam is passed by
- [World Pharma Today "Drug Dosage Forms – Innovations That Shouldn’t Be Given A MISS"](http://boracorpcdmo.com/world-pharma-today-drug-dosage-forms-innovations-that-shouldnt-be-given-a-miss/) - It is critical to manufacturing drugs that get effective usage Except from World Pharma Today's articleAugust 24, 2020 Full Article Manufacturing drugs is one thing but its effective usage is another. Howsoever, complex the treatment or its term be, it all boils down to the dosage and its form. Pharmaceutical Companies today are doing
- [How a CDMO Can Increase The Competitiveness of Your Product](http://boracorpcdmo.com/how-a-cdmo-can-increase-the-competitiveness-of-your-product/) - After 1990, the pharmaceutical industry shifted due to increased R&D spending, changes in the health insurance system, and the competition from new drugs and ones that were going generic. This shift drove increased complexity in supply chain operations. The demand for smaller production scale and shorter fulfillment times have been increasing. In some cases,
- [What Role Does QbD Play in Pharmaceutical Feasibility Studies?](http://boracorpcdmo.com/what-role-does-qbd-play-in-pharmaceutical-feasibility-studies/) - We are often asked, “Why do we need Pharmaceutical Feasibility Studies?”. In the development of a new drug, it is important to note that a feasibility study is probably the single most important consideration. This is where, as your manufacturing partner, we begin to stress and optimize the formula, the process, the equipment train,
- [Bora Pharmaceuticals’ Bobby Sheng wins ‘CEO of the Year’ at CPhI Awards 2020](http://boracorpcdmo.com/bora-pharmaceuticals-bobby-sheng-wins-ceo-of-the-year-at-cphi-awards-2020/) - Bora Pharmaceuticals, a full-service contract development and manufacturing organisation (CDMO) which specialises in immediate and modified release tablets and capsules, along with serialised packaging, announced that its Chairman and CEO, Bobby Sheng, was unveiled as ‘CEO of the Year’ at the CPhI Pharma Awards 2020. The CEO of the Year award is granted to
- [What is a CBE 30 Filing? What is a PAS? What's the Difference Between ANDA and NDA?](http://boracorpcdmo.com/what-is-a-cbe-30-filing-what-is-a-pas-whats-the-difference-between-anda-and-nda/) - Although regulations often vary by region, regulators intend to protect public health. Regulatory authorities are expected to carry out their public health mandates by facilitating the timely introduction of new medicinal products to meet society’s requirements. At the same time, they are responsible for protecting the public from products of suspect quality, safety, and
- [What is the Best Way to Scale-up the Manufacturing Process for My Pharmaceutical Product?](http://boracorpcdmo.com/what-is-the-best-way-to-scale-up-the-manufacturing-process-for-my-pharmaceutical-product/) - Many of the pharmaceutical companies we work with have questions about how to best scale-up the manufacturing process for their products. With the bright promise of ramping sales and distribution comes the immediate challenge of identifying the most optimal manufacturing strategy to maximize their product’s market acceptance. In this article, we’ll take a closer
- [Modified-Release Oral Solid Dosage Technologies](http://boracorpcdmo.com/modified-release-oral-solid-dosage-technologies/) - For pharmaceutical product owners, to enhance their patients’ lives is their ultimate goal. Successful technology transfers ensuring product performance and safety before the product goes to market is paramount. For their manufacturing partners - pharmaceutical contract manufacturers – successful technology transfers between clients and ourselves is our ultimate goal. If technology transfers are successful, then product performance in confirmed, supply hiccups are minimized. Technology transfer
- [Bora Pharmaceuticals completes acquisition of former GSK facility](http://boracorpcdmo.com/bora-pharmaceuticals-completes-acquisition-of-former-gsk-facility/) - Bora Pharmaceuticals Co., Ltd announced today that the contract development and manufacturing organization (CDMO) has successfully completed the acquisition of GSK’s Mississauga, Ontario (Canada) facility. Initially announced in March 2020, the site represents Bora Pharmaceuticals’ first manufacturing facility in North America and will become home to its North American headquarters. Establishing the Mississauga site
- [What are GxPs and How Do They Shape the Quality of Your Pharmaceutical Product?](http://boracorpcdmo.com/what-are-gxps-and-how-do-they-shape-the-quality-of-your-pharmaceutical-product/) - GxP is a general term used to describe the quality guidelines and regulations applied in the pharmaceutical industry. GxP is the abbreviation of “Good x Practice”. The “x” in GxP stands for the field the guidelines and regulations applied to. Here are examples of GxPs often seen in the pharmaceutical industry: GMP - Good
- [Mutual Understanding: The Art of Successful Technology Transfer](http://boracorpcdmo.com/mutual-understanding-the-art-of-successful-technology-transfer/) - Understanding is the foundation of a successful outsourcing relationship. When it comes time to outsource a pharmaceutical project, the drug developer must share the results of their hard work and innovation in the R&D lab or at the production site with the manufacturing contractor. It is vital this manufacturing (and packaging) information is fully understood
- [Scale-up: The Next Mountain to Climb in Technology Transfers](http://boracorpcdmo.com/scale-up-the-next-mountain-to-climb-in-technology-transfers/) - Turning a promising drug candidate into a successful pharmaceutical product involves scaling-up the processes, developed in the research lab, in order that commercial supply can be achieved. The technical hurdles involved in making this transfer can be daunting. Also, it is not uncommon for changes to be made in the manufacturing process and/or chemistry
- [What You Need To Know About Manufacturing OTC Products](http://boracorpcdmo.com/what-you-need-to-know-about-manufacturing-otc-products/) - In the most general terms, an over-the-counter (OTC) product can be described as a medicine available for self-medication that does not require a doctor’s prescription. Self-medication is a common treatment of many routine health problems such as headaches, allergies, and skin conditions. OTC drugs are designed, labeled, and approved by various regulatory agencies around
- [What Is The Difference Between Verification And Validation of Analytical Methods In The Pharmaceutical Industry?](http://boracorpcdmo.com/what-is-the-difference-between-verification-and-validation-of-analytical-methods-in-the-pharmaceutical-industry/) - To submit a filing to the FDA, whether that be an NDA, ANDA, or 505(b)(2), a product owner must provide technical files containing a pharmaceutical product's chemistry, manufacturing, and control (CMC), safety (nonclinical), and efficacy (clinical) testing results before gaining approval and market access. This includes analytical testing procedures for the drug substances and
- [Why Are Feasibility Studies Important For Your Pharmaceutical Product?](http://boracorpcdmo.com/why-are-feasibility-studies-important-for-your-pharmaceutical-product-2/) - A feasibility study is a trial run that tests your manufacturing steps, materials, and equipment to confirm that your process is designed correctly. During a feasibility study, any differences in the process resulting from the scale, materials, or equipment differences will be exposed. Identified Critical Process Parameters (CPP) may need to be adjusted. The knowledge
- [Key Considerations for a Successful Pharmaceutical Tech Transfer](http://boracorpcdmo.com/key-considerations-for-a-successful-pharmaceutical-tech-transfer/) - A pharmaceutical technology transfer or more commonly known as a tech transfer, is a series of knowledge transfers on a drug product and its established manufacturing processes from development to commercial production. It can also mean knowledge transfer about existing products from one manufacturing site to another by a facility change, a company merger, an acquisition,
- [Bora Adds Roller Compactor Capabilities](http://boracorpcdmo.com/bora-adds-roller-compactor-capabilities/) - Bora Pharmaceutical Laboratories, a division of Bora Pharmaceuticals, has added roller compaction technology to its solid dose capability offerings at its Zhunan, Taiwan contract manufacturing and packaging facility. The Zhunan facility is a leader in the manufacture of complex oral solid dose (OSD) formulations with expertise in the use of solvents, Wurster Coating, or
- [Pharmaceutical Technology Transfer: Problems and Solutions](http://boracorpcdmo.com/pharmaceutical-technology-transfer-problems-and-solutions/) - Technology transfer aims to commercialize products successfully at your contract manufacturing organization (CMO) partner site. This means the manufacturing, analytics, packaging, relevant documentation, and professional expertise should be involved in the process. It is inevitable that problems and challenges can be encountered during the technology transfer of any pharmaceutical product. However, by working closely together with
- [What Is The Benefit Of Doing An Engineering Batch In The Pharmaceutical Industry?](http://boracorpcdmo.com/what-is-the-benefit-of-doing-an-engineering-batch-in-the-pharmaceutical-industry/) - Not going to invest in your own new equipment or building a new manufacturing line? Engineering trials and CMOs are here to help! So, your new product is ready for the next step – commercial manufacturing production. You have decided not to invest in new equipment or building a new manufacturing line. You’re now
- [What You Need To Know About Equipment Qualification](http://boracorpcdmo.com/what-you-need-to-know-about-equipment-qualification/) - Equipment qualification is critical in the pharmaceutical industry. The equipment not only includes manufacturing equipment but testing and sampling equipment also to name a few. Even the slightest error or misuse can pose a costly risk and time delay for the pharmaceutical product owner and their manufacturer. So, what is equipment qualification? It is
- [What is Process Validation?](http://boracorpcdmo.com/what-is-process-validation/) - The Process Validation (PV) Guidance from the FDA (January 2011) adopts the product lifecycle concept, emphasizing the expectation that process validation starts with process design and carries throughout the entire lifecycle of a commercial product. During the process qualification stage, the process design is evaluated to determine if the process is capable of consistently delivering quality
- [KYOWA Pharmaceutical Industry Co. Ltd. Partners with Bora Pharmaceuticals to manufacture generic product for filing in Japan](http://boracorpcdmo.com/kyowa-pharmaceutical-industry-co-ltd-partners-with-bora-pharmaceuticals-to-manufacture-generic-product-for-filing-in-japan/) - KYOWA Pharmaceutical Industry Co. Ltd., a premier Japanese pharmaceutical company, has contracted with Bora Pharmaceutical Laboratories Inc. (Zhunan), a division of Bora Pharmaceuticals for the manufacturing of generic product for filing in Japan. KYOWA will be the first Japanese client for Bora’s Zhunan manufacturing site which is already USFDA, MHRA, and TFDA approved. This
- [An overview of topical drug product forms – Part 1](http://boracorpcdmo.com/an-overview-of-topical-drug-product-forms-part-1/) - There has been increased interest in the development of topical drug products as a way to deliver drugs locally, rather than systemically and for diseases that occur in the skin, mucosal surfaces, the eye, and/or wounds of these surfaces. There are reduced side effects and toxicity to other organs compared to systemic delivery. Topical
- [How to reduce change orders in your product's tech transfer](http://boracorpcdmo.com/how-to-reduce-change-orders-in-your-products-tech-transfer/) - In pharmaceutical contract manufacturing, outsourcing your product to the right Contract Development and Manufacturing Organization (CDMO) can be a daunting and concerning task. After conducting the legwork of determining the best fit for a CDMO from capabilities and organizational fit perspective, the next step is working with that vendor on determining costs. Generally speaking,
- [An overview of topical drug product forms – Part 2](http://boracorpcdmo.com/an-overview-of-topical-drug-product-forms-part-2/) - In part two of these blog posts, we will discuss the various types of topical products (ointments, creams, gels, sprays, and lotions), detailing their characteristics both in terms of formulation and use. The Challenges As discussed earlier, there has been an increase in the development of topical drug products as a way to deliver
- [What is the best way to ensure a smooth technology transfer from one pharmaceutical manufacturing facility to another?](http://boracorpcdmo.com/what-is-the-best-way-to-ensure-a-smooth-technology-transfer/) - There are many benefits to using a pharmaceutical contract manufacturer (CMO). Many small to mid-sized pharmaceutical companies utilize them for developing their drugs when they don’t have their own facilities. For those companies that have already developed their pharmaceutical product or have licensed in a drug product, CMOs are a great place to transfer their existing
- [The legacy of Mississauga's leadership in Environment, Health and Safety](http://boracorpcdmo.com/the-legacy-of-mississaugas-leadership-in-environment-health-and-safety/) - As part of Bora Pharmaceuticals’ global growth strategy, the company successfully completed the acquisition of GSK's Mississauga, Ontario (Canada) facility in 2020. Representing Bora’s first manufacturing facility in North America and its headquarters in the region, the Mississauga site is integral to the company’s global contract development and manufacturing organization (CDMO) business offering. With
- [Bora Pharmaceuticals acquires Eden Biologics CDMO Assets](http://boracorpcdmo.com/bora-pharmaceuticals-acquires-eden-biologics-cdmo-assets/) - Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market Taiwan-based premier international contract development and manufacturing organization (CDMO) Bora Pharmaceuticals recently announced the establishment of Bora Biologics Co., Ltd., a CDMO platform for biologics. Besides Bora, investors into the new entity include Taishin Healthcare Limited
- [Supply chain disruptions and their impact on quality and operations](http://boracorpcdmo.com/supply-chain-disruptions-and-their-impact-on-quality-and-operations/) - COVID-19’s impact on global supply chains as well as tectonic geopolitical shifts have resulted in considerable disruption, particularly to the contract development and manufacturing organization (CDMO) industry. Looking back, what is troubling about the supply chain challenges CDMOs faced during the past three years is that they were very similar to the issues plaguing many
- [Why it can take so long to validate pharmaceutical manufacturing processes during site-to-site technology transfers and what can be done to speed it up](http://boracorpcdmo.com/why-it-can-take-so-long-to-validate-pharmaceutical-manufacturing-processes/) - Process validation too slow? Here’s how to speed things up Technology transfers and process validation are an integral part of drug development and commercial drug product manufacturing. Successful technology transfer from site-to-site requires careful evaluation of manufacturing requirements and consequently applying that wisdom to validate a robust process that supports commercial-scale quality and production
- [Bora expands its CMDO capabilities as it makes landmark acquisition of TWi Pharmaceuticals](http://boracorpcdmo.com/bora-expands-its-cmdo-capabilities-as-it-makes-landmark-acquisition-of-twi-pharmaceuticals/) - Bora establishes a lead position in Taiwan's CDMO sector TAIWAN - Fast-growing contract development and manufacturing organization (CDMO), Bora Pharmaceuticals, has completed the acquisition of TWi Pharmaceutical Co.Ltd, a technology-based company specializing in development and commercialization of niche generic drugs. Acquiring TWi Pharmaceuticals adds two manufacturing facilities and will significantly boost Bora’s service offerings in
- [Bora Pharmaceuticals Featured in Fierce Pharma - Bora's Quest to Join Ranks of Top CDMOs](http://boracorpcdmo.com/bora-pharmaceuticals-featured-in-fierce-pharma-boras-quest-to-join-ranks-of-top-cdmos/) - Fierce Pharma features a discussion with CEO, Bobby Sheng in an article entitled "After Bora's biologics debut, CEO outlines quest to join ranks of top CDMOs". Published on November 10, 2022Thank you Fierce Pharma and author Fraiser Kansteiner Bora's focus on customer partnership is key to Bora's acquisition strategy. Bora's recent addition of biologics
- [Bora Pharmaceuticals Featured in Pharma Intelligence Generic Bulletin](http://boracorpcdmo.com/bora-pharmaceuticals-featured-in-pharma-intelligence-generic-bulletin/) - Bora Pharmaceuticals is mentioned as "the largest pharmaceutical group by volume in Taiwan" in 2022 after completing the company's "landmark acquisition" of TWi Pharmaceuticals. Published in the online version of Generics Bulletin. https://generics.pharmaintelligence.informa.com/GB152440/Standalone-Sandoz-And-Biocons-Biosimilars-2022s-Biggest-Deals Thank you Pharma Intelligence andAuthor Dean RudgePublished: January 18, 2023
- [Bora Pharmaceuticals Featured in Pharma Manufacturing - Three Fast Growing CDMOs to Watch](http://boracorpcdmo.com/bora-pharmaceuticals-featured-in-pharma-manufacturing-three-fast-growing-cdmos-to-watch/) - Read Pharma Manufacturing's feature article entitled "Built to Thrive: Three CDMOs that set themselves up to flourish" Published on February 7, 2023Thank you Pharma Manufacturing and author Karen Longhauser Pharma Manufacturing's feature article positions Bora as one of three fast growing CDMOs to watch. In their interview with Bora CEO, Bobby Sheng, the author
- [How roller compaction helps dry powder formulations go with the flow](http://boracorpcdmo.com/how-roller-compaction-helps-dry-powder-formulations-go-with-the-flow/) - Importance of good flow Good powder flow is particularly important when manufacturing tablets and capsules because rapid and accurate filling of the tablet die or capsule body is essential to achieve consistent weights, and thus, a consistent drug dose. When powdered active pharmaceutical ingredients (API) possess poor flow characteristics, they present a handling challenge Explore how roller compaction helps to improve the content uniformity and flow of powder blends when manufacturing tablets and capsules, the most common oral solid oral dosage (OSD) forms.
- [Enzyme experience key to commercializing novel  blood diagnostic device](http://boracorpcdmo.com/enzyme-experience-key-to-commercializing-novel-blood-diagnostic-device/) - Cell line development insight boosts active protein productivity more than five times Q-Sera, an internationally recognized biotech innovator engaged Bora’s team to develop and manufacture an innovative active protein, RAPClot™ (ecarin), a key component of its proprietary coating to improve the function of a serum-based blood testing device. Blood collection tubes are coated with Explore how roller compaction helps to improve the content uniformity and flow of powder blends when manufacturing tablets and capsules, the most common oral solid oral dosage (OSD) forms.
- [Bora Pharmaceuticals Featured in Contract Pharma - Extrusion-Spheronization Delivery in OSD Manufacturing](http://boracorpcdmo.com/bora-pharmaceuticals-featured-in-contract-pharma-extrusion-spheronization-delivery-in-osd-manufacturing/) - Contract Pharma features this engaging article: "Extrusion-Spheronization in OSD Manufacturing. How extrusion-spheronization excels delivering controlled and modified release dose forms." Published on February 21, 2023Contract Pharma In this article Bora explores delivery solutions enabled by the E-S manufacturing process and improved modified release dosage forms as well as improved patient outcomes. Read the
- [Bora Group Partnering with Leading Universities for Campus Recruitment Events](http://boracorpcdmo.com/bora-group-partnering-with-leading-universities-for-campus-recruitment-events/) - Join the Bora Team! Bora Group, is partnering with leading universities in Taiwan to meet with students who are interested in joining the clinical development and manufacturing industry. Bora has invested heavily in growth over the last 5 years and has high demand for many positions. Bora will present at the following universities and
- [How enhancing equipment reliability supports quality, efficiency, and operational excellence](http://boracorpcdmo.com/how-enhancing-equipment-reliability-supports-quality-efficiency-and-operational-excellence/) - Importance of equipment reliability Successfully manufacturing a drug product requires people, proper equipment, and materials. It’s the classic three-legged stool analogy. Even with well-trained staff and high-quality materials, if the equipment does not function as expected, or is not reliable, the final product can never be cost-effectively produced. Product quality will likely be compromised How optimizing equipment maintenance and management strategies increase reliability and reduce operating costs.
- [Bora Pharmaceuticals and Celltrion Partners to Expand OSD capabilities in APAC market](http://boracorpcdmo.com/bora-pharmaceuticals-and-celltrion-partners-to-expand-osd-capabilities-in-apac-market/) - Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”) and Celltrion Asia Pacific Pte., Ltd. (“Celltrion”), a subsidiary of Celltrion Group Inc, have today announced their partnership to contract manufacture and commercialize a range of oral dosage form drugs (OSD) across the APAC region. The range of oral dosage form products will be manufactured at
- [Bora Pharmaceuticals Featured in Biopharma Reporter - How Bora is moving into biologics and attempting to crack North America](http://boracorpcdmo.com/bora-pharmaceuticals-featured-in-biopharma-reporter-how-bora-is-moving-into-biologics-and-attempting-to-crack-north-america/) - In this article, Bora discusses its expansion efforts and plans to provide services in the United States. In the large molecule space, Bora offers comprehensive services from the development of mammalian cell lines through cGMP production of drug substance. Read the article
- [Bora Pharmaceuticals Featured in Contract Pharma - What are 3 Key Trends shaping the CDMO industry in 2023 and beyond?](http://boracorpcdmo.com/bora-pharmaceuticals-featured-in-contract-pharma-what-are-3-key-trends-shaping-the-cdmo-industry-in-2023-and-beyond/) - Read Contract Pharma - "What are 3 Key Trends shaping the CDMO industry in 2023 and beyond?" Published on June 22, 2023 Bobby Sheng sheds some light on the three main trends impacting CDMOs in 2023 - and potentially for many years ahead. One such trend is an increased demand for the production of
- [Bora Pharmaceuticals is Awarded Outstanding Company of the Year at Bio-Asia Taiwan 2023](http://boracorpcdmo.com/bora-pharmaceuticals-is-awarded-outstanding-company-of-the-year-at-bio-asia-taiwan-2023/) - Bora has been awarded "Outstanding Company of the Year" by an independent panel of international judges during Bio-Asia Taiwan exhibit taking place in Taipei, Taiwan July 24-26, 2023. Bora was chosen from a short list of several candidates for its demonstrated leadership in the Taiwan Biopharma industry. Bobby Sheng said; "Our team's focused dedication
- [Bora Pharmaceuticals unveils eye-opening new facility for Ophthalmic manufacturing](http://boracorpcdmo.com/bora-pharmaceuticals-unveils-eye-opening-new-facility-for-ophthalmic-manufacturing/) - Taiwan, 31st July 2023: Bora Pharmaceuticals, a leading contract development and manufacturing organization (CDMO), is pleased to announce the opening of a new state-of-the-art facility in Taoyuan City, Taiwan. Officially opened by Bora Pharmaceuticals CEO Bobby Sheng and President of Taiwan Operations Tom Chang, the facility will provide Bora’s customers with access to an extensive range
- [The benefits of CDMOs with customer-centric approaches and cohesive teams](http://boracorpcdmo.com/the-benefits-of-cdmos-with-customer-centric-approaches-and-cohesive-teams/) - In the highly competitive and rapidly evolving biopharma industry, choosing the right contract development and manufacturing organization (CDMO) is a critical decision that can significantly impact the success of a pharmaceutical development journey. When exploring potential CDMO partners, two key factors to consider are whether the company has a customer-centric approach, and if the How optimizing equipment maintenance and management strategies increase reliability and reduce operating costs.
- [CPhI Barcelona 2023](http://boracorpcdmo.com/cphi-barcelona-2023/) - October 24-26, 2023 Fira Barcelona Booth #3D38
- [Bio Japan 2023](http://boracorpcdmo.com/bio-japan-2023/) - October 11-13, 2023 PACIFICO Yokohama, Japan Booth #B-19
- [22nd Annual Contracting & Outsourcing Conference](http://boracorpcdmo.com/22nd-annual-contracting-outsourcing-conference/) - September 21-22, 2023 Hyatt Regency New Brunswick Table 91​
- [BLOG - Scaling biologics development for commercial success](http://boracorpcdmo.com/scaling-biologics-development-for-commercial-success/) - Learn how adopting a customer-centric approach with a CDMO partner can help biologics developers overcome scaling challenges and ensure a smooth transition to commercial production.
- [Customized solutions for biologics development: leveraging adaptive platforms to meet customer needs](http://boracorpcdmo.com/customized-solutions-for-biologics-development/) - The rapidly growing numbers of monoclonal antibodies (mAbs), fusion proteins and biosimilars produced by the pharma industry have greatly improved patient care and resulted in a proliferation of innovative treatment options. To date, there are over 100 biosimilars [1, 2], 162 mAbs [3] and over 11 fusion proteins [4] approved for therapeutic use. These Customized solutions for biologics development: leveraging adaptive platforms to meet customer needs
- [Strategies and tactics for success in biologics analytical testing](http://boracorpcdmo.com/strategies-and-tactics-for-success-in-biologics-analytical-testing/) - In pharmaceutical contract manufacturing, outsourcing your product to the right Contract Development and Manufacturing Organization (CDMO) can be a daunting and concerning task. After conducting the legwork of determining the best fit for a CDMO from capabilities and organizational fit perspective, the next step is working with that vendor on determining costs. Generally speaking, there Customized solutions for biologics development: leveraging adaptive platforms to meet customer needs

## Pages

- [Home](http://boracorpcdmo.com/) - Bora Pharmaceuticals Premium CDMO
- [Cookie Policy (EU)](http://boracorpcdmo.com/cookie-policy-eu/) - This Cookie Policy was last updated on April 27, 2026 and applies to citizens and legal permanent residents of the European Economic Area and Switzerland. 1. Introduction Our website, http://boracorpcdmo.com (hereinafter: "the website") uses cookies and other related technologies (for convenience all technologies are referred to as "cookies"). Cookies are also placed by third parties
- [Leadership Team](http://boracorpcdmo.com/about-3/team/) - Bobby Sheng Group CEO & Chairman J.D. Mowery President, CDMO Business Simon Chen Vice President, R&D Alice Wang CFO, HQ & APAC JB Agnus Chief Commercial Officer Tom Chang President, Bora Pharmaceutical Laboratories Inc. John Lawrie Vice President, Operations Goff Baker VP of Quality Frank Chen VP of IT Stefan Schnydrig Senior VP & Chief
- [Careers at Bora](http://boracorpcdmo.com/about-3/careers/) - Unprecedented Growth Bora Pharmaceuticals is experiencing unparalleled growth as we transform and add new clients. This requires extraordinary talent with many different skills to join our team to provide exceptional service to our clients. Do you have the right drive, attitude, and determination to help contribute to Bora’s growth? Explore Open Roles 0 + Employees
- [Manufacturing Locations​](http://boracorpcdmo.com/about-3/locations/) - From our state-of-the-art cGMP manufacturing facilities across North America and Taiwan, Bora supplies drug product to more than 100 countries. Learn more below. BALTIMORE, MD, USA MISSISSAUGA, ON, CANADA MAPLE GROVE, MN, USA TAINAN, TAIWAN TAOYUAN, TAIWAN ZHONGLI, TAIWAN ZHUNAN, TAIWAN
- [Zhunan, Taiwan](http://boracorpcdmo.com/about-3/locations/zhunan/) - Zhunan Facility Our 36,000 square meter Zhunan, Taiwan facility is designed for flexible, high-quality contract Oral Solid Dose (OSD) cGMP drug manufacturing. The facility offers best-in-class capabilities and access to the largest pharmaceutical markets in the world, including North America and the European Union. Bora’s contract manufacturing teams offer expert formulation development, pilot/pivotal manufacturing and
- [Tainan, Taiwan](http://boracorpcdmo.com/about-3/locations/tainan/) - Tainan Facility Designed for flexible, high-quality, contract solid dose CGMP drug manufacturing, Bora’s site in Tainan, Taiwan offers best-in-class capabilities and access to unique pharmaceutical markets in Southeast Asia, the Middle East, and Latin America. From our operations in Tainan, Bora contract manufacturing teams offer expert manufacturing and commercialization services for a broad range of
- [Maple Grove, MN](http://boracorpcdmo.com/about-3/locations/maple-grove-mn/) - Minnesota facilities We operate two state-of-the-art manufacturing sites in Minnesota. Our Maple Grove facility features 170,000 square feet of finished GMP space, with an additional 100,000 square feet available for future expansion. This site is equipped with serialization and aggregation capabilities and offers comprehensive contract manufacturing services. Our second, smaller facility in Plymouth focuses on
- [Mississauga, ON](http://boracorpcdmo.com/about-3/locations/mississauga-on/) - Mississauga Facility Our 170,000 square meter Mississauga, Ontario facility is designed for flexible, high-quality, cGMP drug contract manufacturing, offering unique capabilities and experience to supply the largest pharmaceutical markets in the world. From our North American headquarters, Bora contract manufacturing teams offer expert development, manufacturing, packaging, and commercialization services for oral solid dose (OSD), liquid,
- [Baltimore, MD](http://boracorpcdmo.com/about-3/locations/baltimore-md/) - Our 87,000 square foot cGMP facility in Baltimore, MD, USA provides drug product manufacturing services for sterile injectables, specializing in aseptic fill/finish manufacturing, packaging, analytical services, and on-site testing and support services for clinical and commercial drug products. This site has extensive experience in tech transfer, scale-up, and commercial production of both small molecules and
- [Taoyuan, Taiwan](http://boracorpcdmo.com/about-3/locations/taoyuan/) - Taoyuan Facility Our 6,891 square meter Taoyuan, Taiwan facility is designed specifically to develop and manufacture Ophthalmic solutions, suspensions, nano-suspensions including nano-emulsions, ointments and gel products. Manufacturing Locations From our state-of-the-art cGMP manufacturing facilities across North America and Taiwan, Bora supplies drug product to more than 100 countries. Learn more below. BALTIMORE, MD, USA MISSISSAUGA,
- [Zhongli, Taiwan](http://boracorpcdmo.com/about-3/locations/zhongli/) - Zhongli Facility Our 14,059 square meter Zhongli, Taiwan facility is designed for flexible, high-quality contract liquids, semi-solid and oral solid cGMP drug manufacturing. The facility offers best-in-class capabilities and access to the largest pharmaceutical markets in the world, including North America, European Union and China. Manufacturing Locations From our state-of-the-art cGMP manufacturing facilities across
- [Ophthalmic](http://boracorpcdmo.com/dosage-forms/ophthalmic/) - Commercial ophthalmic manufacturing ​The known advantages of the ocular route of drug administration is that it ensures that the drug substance is available in higher concentrations than oral administration. As the population ages, ophthalmic solutions are increasingly in demand. Recently there has been success of a number of drugs, both utilizing NCEs and previously approved
- [Resources](http://boracorpcdmo.com/resources/) - Home
- [About Bora Pharmaceuticals](http://boracorpcdmo.com/about-3/) - Who We Are Bora Pharmaceuticals is a contract development and manufacturing organization (CDMO) specializing in complex oral solid dosage (tablet & capsules), biologics, liquids (solutions, suspensions, ophthalmics & nasal sprays), powders, semi-solids (creams, ointments & gels), and sterile injectables for pharmaceutical products for Clinical through Commercial manufacturing and packaging. Contact An Expert Global Presence Bora owns and operates ten state-of-the-art cGMP manufacturing facilities (Taiwan, Canada, and the
- [Zhubei, Taiwan](http://boracorpcdmo.com/about-3/locations/asia/zhubei/) - Zhubei Facility Our 4,500 square meter Zhubei, Taiwan facility can support preparation and purification of the most complex proteins or provide one to hundreds of monoclonal, bispecific and multispecific antibodies and other recombinant proteins for your diverse needs including early-stage discovery research, lead candidate screening, in vivo studies, biochemical assays, crystal structure analysis, and other
- [Wuster Coating](http://boracorpcdmo.com/technologies/wuster-coating/) - For superior controlled-release oral solid dosage forms Wurster coating is one of the most recognized methods for developing effective controlled-release formulations as it enables a highly consistent coating of powders, granules, pellets, and micro-tablets. The technology involves bottom-spray fluid bed coating of particles with appropriate actives, excipients, or polymers to modify the drug release. Expertise
- [Extrusion Spheronization](http://boracorpcdmo.com/technologies/extrusion-spheronization/) - For complex encapsulated controlled-release OSD therapeutics​ Extrusion-spheronization as a drug delivery strategy has achieved tremendous success in improving safety, efficacy, and dose compliance across a diverse range of therapeutic areas. Our formulation skills and experience with the mechanisms of continuous-flow extrusion-spheronization support a broad range of controlled release dose forms including fixed-dose combinations (FDCs), combined
- [Modified Release](http://boracorpcdmo.com/technologies/modified-release/) - Proven track record in modified-release dosage forms Modified-release dosage forms can enhance the safety, efficacy, reliability, and convenience of drug therapy by controlling the rate and duration of drug release. Technology transfers for modified-release oral solid dose (OSD) drugs are particularly challenging. CDMOs with experience in these technologies are more likely to succeed in transferring
- [Handling Solvents](http://boracorpcdmo.com/technologies/handling-solvents-2/) - Safe and secure solvent handling and processing We understand the importance of Organic Solvents as critical intermediates in the drug manufacturing process. That’s why we’re dedicated to the safe handling and processing of solvents, putting top-class equipment and robust processes in place to protect personnel, patients, the environment, and industry reputation. State-of-the-art dedicated solvent handling
- [Sterile Injectables](http://boracorpcdmo.com/dosage-forms/sterile-injectables/) - Flexible and scalable fill/finish manufacturing solutions As the demand for sterile injectable medicines grow, partnering with an experienced fill/finish manufacturer with the specialized capabilities, expertise, and capacity to safely and efficiently scale production is critical in strengthening your supply chain and delivering essential therapies to patients worldwide. Bora’s drug product manufacturing facility located in Baltimore,
- [Stability Testing and Storage](http://boracorpcdmo.com/development-analytical-services/stability-testing-storage/) - Looking for a trusted partner to bring your breakthrough drug successfully to the market? Reliable and consistent stability testing is a prerequisite to collect valuable data about drug product quality variations over time under a variety of environmental conditions including temperature, humidity, and light exposure. At Bora, we use state-of-the-art ESI and Hsinron stability chambers
- [Analytical Testing](http://boracorpcdmo.com/development-analytical-services/analytical-testing/) - A one-stop solution for all your analytical testing needs Our analytical teams are highly experienced in method development, transfer, validation, and verification against regulatory compendia such as USP and/or EP for raw material / finished product analysis, ICH for stability storage and testing, etc. Contact a Bora Expert Bora offers a full-service, comprehensive range of
- [Analytical Development](http://boracorpcdmo.com/development-analytical-services/analytical-development-2/) - Comprehensive analytical method development services Analytical offerings are specifically customized to our clients’ needs based on development phase and dosage form. We are able to test to current USP, Ph.Eur., JP and other compendia. Expert-led analytical research and development team Bora’s cohesive and interdisciplinary analytical team are comprised of highly skilled analytical chemists, drug development
- [Formulation Development](http://boracorpcdmo.com/development-analytical-services/formulation-development/) - Find the flexibility your formulation needs We are proud to help our partners’ innovations reach patients faster by accelerating program agility earlier in development. Bora’s formulation development teams have experience supporting commercial development and manufacturing strategies across a wide range of drug programs. With a specialized focus on oral solid dose (OSD) drug substance and
- [Scale-Up and Commercial](http://boracorpcdmo.com/manufacturing-packaging/scale-up-commercial/) - Scale up to minimize risks and control costs A long history of successful tech transfer and scale up to commercial Having completed over 40 drug product tech transfers and scale-ups over the years, Bora’s Project Managers have demonstrated a long track record of successfully managing time, expenses, risks, and schedules to make any challenging drug
- [Packaging & Serialization](http://boracorpcdmo.com/manufacturing-packaging/packaging-serialization/) - Pharma packaging and labeling Bora has complete pharma packaging and labeling offering for Rx and OTC products. We have the capacity and operational excellence you need to package and serialize virtually all commercial oral solid, semi-solid, and liquid dosage forms, including non-sterile nasal spray bottles. Pharma packaging and labeling operations are segregated between primary and
- [Small Scale and Pilot](http://boracorpcdmo.com/manufacturing-packaging/small-scale-and-pilot/) - Customized and fully aligned to your commercialization strategy Dedicated suites for flexible small-scale cGMP manufacturing At Bora’s North American sites in Mississauga, Ontario and Maple Grove, Minnesota, we operate dedicated suites for small-scale cGMP manufacturing with capacities ranging from 2.5 kg to 125 kg. The suites can accommodate a variety of dosage forms – solid
- [Semi-Solids](http://boracorpcdmo.com/dosage-forms/semi-solids/) - A long history of successful tech transfer Semi-solid dosage manufacturing warrants specialized expertise to achieve therapeutically effective, consistent, and high-quality finished drug products. At Bora, we combine our long history of successful tech transfer with our technical and analytical expertise and flexible manufacturing capacities to manufacture and package a broad range of prescription and over-the-counter
- [Liquids](http://boracorpcdmo.com/dosage-forms/liquids/) - Proven expertise in non-sterile liquid dosage forms Liquid dosage forms, although preferred over OSDs for certain applications such as pediatrics and early phase clinical trials, come with manufacturing challenges. Bora’s strong track record in manufacturing and packaging liquid dosage forms speaks for itself. Our technical and analytical teams have the expertise to manufacture and package
- [Oral Solid Dose](http://boracorpcdmo.com/dosage-forms/solid-oral-dose/) - Flexible and integrated solutions for tablet and capsule manufacturing Oral solid dose (OSD) continues to be the dominant dosage form for pharmaceutical therapeutics with drug developers and manufacturers innovating to develop more therapeutically effective and patient-friendly formulations. Bora provides customized cGMP manufacturing and packaging services for a broad range of OSD tablets and capsules– from
- [Nasal Spray](http://boracorpcdmo.com/dosage-forms/nasal-spray/) - Bora manufactures Prescription (Rx) and Over-the Counter (OTC) nasal sprays Nasal sprays are a great way to deliver drugs to mucosal membranes and potentially the Central Nervous System. Many of these are packaged in a delivery device that makes them a drug device combination product. Additionally, drug manufacturers must overcome several technical and analytical challenges
- [Contact Us](http://boracorpcdmo.com/contact-us/) - Bora Pharmaceuticals is a contract development and manufacturing organization (CDMO) specializing in complex oral solid dosage (tablet & capsules), biologics, liquids (solutions, suspensions, ophthalmics & nasal sprays), powders, semi-solids (creams, ointments & gels), and sterile injectables for pharmaceutical products for Clinical through Commercial manufacturing and packaging. Contact Us to discuss how our comprehensive CDMO solutions, expansive global network, and impeccable Bora service can help make your success
- [Project Management](http://boracorpcdmo.com/biologics/project-management/) - Driving success: Bora Biologics’ PMO commitment to client satisfaction Bora Biologics’ Project Management Organization (PMO) is dedicated to ensuring the successful fulfillment of our clients’ goals and expectations. Through meticulous project planning, execution, and comprehensive monitoring and reporting, our seasoned project managers serve as invaluable single points of contact. With a focus on understanding all
- [Quality Management](http://boracorpcdmo.com/biologics/quality-management/) - Quality – the foundation of Bora Biologics Millions of patients worldwide rely on the safe and consistent production of biopharmaceutical medicines. At Bora Biologics, our unwavering commitment, expertise, and experience ensure the quality of every step, from transfection to the release of each new batch. With a steadfast dedication to robust quality control and reliable
- [Manufacturing](http://boracorpcdmo.com/biologics/bio_manufacturing/) - Flexible single-use manufacturing technologies at an advanced global site Our facility employs state-of-the-art single use mammalian cell culture technologies in upstream and downstream process development mirrored in design with our cGMP manufacturing for consistent and robust tech transfer and scale-up. From cell line development through cGMP production along with associated analytical development and validation, Bora
- [Analytical & Formulation Development](http://boracorpcdmo.com/biologics/analytical-formulation-development/) - Full Range of Analytical Development Capabilities Bora Biologics fully supports method development & qualification, tech transfer & optimization, and method validation. Our broad analytical portfolio enables Bora to provide testing of the structural and physicochemical drug attributes, and to assess binding and functional activities with regards to the mode-of-action. Read our special article to explore
- [Cell Line & Process Development](http://boracorpcdmo.com/biologics/cell-line-process-development/) - Download our eBook and learn how a robust CLD strategy can help biologics developers anticipate and overcome challenges and streamline production. Download Now Proprietary host cell-line and high-expression vector provide superb production efficiency Bora generates high performance production cell lines under a target product profile using our proprietary CHO expression technologies. With the implementation of a state-of-the-art
- [Sustainability](http://boracorpcdmo.com/sustainability/) - Sustainability is our Priority Bora Pharmaceuticals takes a sustainable stance on all of our operations. We are continuously working towards becoming more sustainable and to mitigate any negative impact we have on the world. In response to climate change and reducing our impact, we are transparent with our current sustainability efforts and so, we
- [Culture](http://boracorpcdmo.com/about-3/culture/) - Bora’s culture shines because it is STAR powered Our people-first mindset is an operating priority, one that has allowed the company and its people to foster and maintain an open, friendly working environment, across every site, underpinned by our STAR culture. Solve problems first To do the right thing Always be proactive Respect everyone Get to
- [Quality](http://boracorpcdmo.com/quality-4/) - Manufacturing Operations Pharmaceutical quality is the foundation by which Bora seeks to further differentiate ourselves by ensuring all requirements for drug and OTC product manufacturing operations comply with the ever-changing regulatory landscape, as well as the specific requirements of our customers’ marketing authorizations approved by various global regulatory agencies. We do this because it is
- [Dosage Forms](http://boracorpcdmo.com/dosage-forms/) - Diverse small molecule drug product manufacturing and packaging capabilities Leverage Bora’s premium contract manufacturing offerings for oral solid doses (OSD), semi-solids, liquids, nasal sprays, and ophthalmics using state-of-the-art technologies to get your prescription (Rx) and OTC medicines reliably and faster to patients around the world. Flexible and integrated solutions for biologics From cell-line, process and formulation development and analytical services to cGMP manufacturing and fill/finish,
- [Why Choose Bora Pharmaceuticals](http://boracorpcdmo.com/about-3/why-choose-bora/) - The Bora Pledge As a future focused CDMO, we know better than most that our own success is shaped by our partners victories. That’s why, when you choose Bora – we make success more certain by following Bora’s 5Ps – Promises, Partnerships, Pride, People, and Progress. These 5 principles are Bora’s Pledge to our customers.
- [Manufacturing & Packaging](http://boracorpcdmo.com/manufacturing-packaging/) - Your reliable full-service partner with a broad expertise Bora offers the full spectrum of pharma contract manufacturing and packaging services for a range of drug products (DPs), including complex oral solids, liquids, semi-solids, and sterile injectables at clinical and commercial scales. Bora has the capabilities, skilled talent, and technologies to offer flexible manufacturing and packaging
- [North America](http://boracorpcdmo.com/about-3/locations/north-america/) - North American Locations Bora Pharmaceuticals offers a wide range of development and manufacturing solutions for small and large molecules from four high-end facilities throughout North America: Mississauga, Canada; Baltimore, Maryland; Maple Grove and Plymouth, Minnesota. From these sites, we provide best-in-class contract drug development, manufacturing, analytical, QC, packaging, labeling, serialization services for a broad range
- [Technologies](http://boracorpcdmo.com/technologies/) - A Premium CDMO with Complex Capabilities Bora’s capabilities cover a wide range of technologies for clinical and commercial manufacturing of oral solids, semi-solids, and liquids in various forms – tablets, capsules, granules, liquids, semi-solids, and nasal sprays. Contact an Expert Find the perfect technology-drug product match Successful drug development relies on matching the needs of
- [Biologics](http://boracorpcdmo.com/biologics/) - Flexible and integrated solutions for biologics development and cGMP manufacturing From cell-line, process and formulation development and analytical services to clinical cGMP manufacturing and fill/finish, Bora Biologics provides end-to-end and tailored development and manufacturing services to biologics developers. Bora has the capability to deliver high-yield processes and the program management needed to launch even the most challenging molecules successfully. Read our article to explore the
- [Development & Analytical Services](http://boracorpcdmo.com/development-analytical-services/) - Explore, Develop and Optimize Pharma’s development pipeline is becoming increasingly complex with more sophisticated, harder to manufacture compounds. From early-stage New Chemical Entities (NCEs), 505(b)(2), to generic products, Bora offers specialist expertise to our partners to explore, develop and optimize formulation, processes, and analytical methods to achieve therapeutic goals and improve value to patients. Deliver
- [Asia Locations](http://boracorpcdmo.com/about-3/locations/asia/) - Our Asian Headquarters Bora Pharmaceuticals in headquartered in Taipei, Taiwan with five manufacturing sites in Tainan, Zhunan, Zhongli, Taoyuan, and Zhubei. From these five sites, we provide best-in-class, cGMP contract drug manufacturing, packaging, labeling, and serialization services for a broad range of oral solid dose (OSD), liquids, semi-solids and ophthalmic therapeutics as well as biologics
- [Accessibility](http://boracorpcdmo.com/about-3/accessibility/) - Bora Pharmaceuticals Services Inc. is committed to meeting the needs of persons with disabilities in a timely manner by identifying, preventing and removing barriers to accessibility and meeting accessibility standards in accordance with the Accessibility for Ontarians with Disabilities Act, 2005 (the “AODA“) and the Integrated Accessibility Standards regulation (the “IASR“). Accessibility Policies Bora is committed to creating a
- [Biologics Test](http://boracorpcdmo.com/biologics-test/) - [et_pb_section fb_built="1" admin_label="Header Title" _builder_version="4.18.0" _module_preset="ab86d6a0-7a87-4d93-ada0-7ae089aa18ca" background_image="http://boracdmo.com/wp-content/uploads/sites/2/2022/10/dreamstime_xxl_165659229-scaled-e1664943355563.jpg" background_position="top_center" min_height="275px" custom_padding="0px||0px||true|false" custom_css_main_element="display: flex;" collapsed="off" global_colors_info="{}"][et_pb_row _builder_version="4.16" _module_preset="default" min_height="142.7px" custom_margin="|auto|64px|auto||" custom_padding="|||69px||" global_colors_info="{}"][et_pb_column type="4_4" _builder_version="4.16" _module_preset="default" global_colors_info="{}"][et_pb_text admin_label="Title" _builder_version="4.25.0" _module_preset="f7d4d149-ed0f-4740-a0be-5f2022f96189" text_font_size="36px" header_font="Century Gothic||||||||" header_text_color="#3F3A39" header_font_size="50px" header_2_font="Century Gothic||||||||" header_2_text_color="#3F3A39" header_2_font_size="42px" header_3_font="Century Gothic||||||||" header_3_text_align="center" header_3_text_color="#3F3A39" header_3_font_size="38px" header_3_line_height="1.4em" header_4_font="Century Gothic||||||||" header_4_text_color="#005081" header_4_font_size="30px" header_4_line_height="1.4em" header_5_text_color="#3F3A39" header_5_font_size="25px" header_6_font="Century Gothic Bold||||||||" header_6_text_color="#3F3A39" header_6_font_size="20px" max_width="900px"
- [Analytical](http://boracorpcdmo.com/biologics/bio_analytical/) - [et_pb_section fb_built="1" admin_label="Header Title" _builder_version="4.18.0" _module_preset="b0568527-19ff-490f-b1f2-8be7d12d96d9" background_image="http://boracdmo.com/wp-content/uploads/sites/2/2022/10/dreamstime_xxl_165659229-scaled-e1664943355563.jpg" background_position="center" collapsed="off" global_colors_info="{}"][et_pb_row _builder_version="4.16" _module_preset="8b587aaa-73a0-4dc8-8124-af875bb8ccdf" min_height="142.7px" custom_margin="|auto|64px|auto||" custom_padding="|||69px||" global_colors_info="{}"][et_pb_column type="4_4" _builder_version="4.16" _module_preset="default" global_colors_info="{}"][et_pb_text admin_label="Title" _builder_version="4.19.5" _module_preset="57d44031-e63c-4121-af33-69d27336dc8a" text_font_size="36px" min_height="117.7px" hover_enabled="0" global_colors_info="{}" sticky_enabled="0"] Analytical [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built="1" admin_label="Breadcrumb section" _builder_version="4.14.8" _module_preset="a827bbeb-f98d-4efb-b0e8-f296faeedfe1" min_height="30.2px" custom_padding="5px||0px||false|false" global_module="242477" saved_tabs="all" collapsed="on" global_colors_info="{}"][/et_pb_section][et_pb_section fb_built="1" admin_label="A Premium CDMO" _builder_version="4.16" _module_preset="default" min_height="386.9px" custom_padding="0px||0%||false|false" locked="off" collapsed="on" global_colors_info="{}"][et_pb_row column_structure="1_2,1_2" _builder_version="4.16" _module_preset="default"
- [Plan du site](http://boracorpcdmo.com/plan-du-site/) - [et_pb_section fb_built="1" admin_label="section" _builder_version="4.14.8" hover_enabled="0" global_colors_info="{}" _module_preset="6dd0dd9d-6697-4057-a17e-75f8f5ce03b9" sticky_enabled="0" collapsed="on"][et_pb_row admin_label="row" _builder_version="3.25" background_size="initial" background_position="top_left" background_repeat="repeat" global_colors_info="{}"][et_pb_column type="4_4" _builder_version="3.25" custom_padding="|||" global_colors_info="{}" custom_padding__hover="|||"][et_pb_text _builder_version="4.14.8" _module_preset="default" hover_enabled="0" sticky_enabled="0"] Plan du site [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
- [Thank you](http://boracorpcdmo.com/newsletter-thank-you/) - [et_pb_section fb_built="1" admin_label="Header Title" _builder_version="4.18.0" _module_preset="b0568527-19ff-490f-b1f2-8be7d12d96d9" hover_enabled="0" collapsed="off" global_colors_info="{}" sticky_enabled="0" background_image="http://boracdmo.com/wp-content/uploads/sites/2/2022/09/dreamstimemaximum_28514554-scaled-1.jpg"][et_pb_row _builder_version="4.16" _module_preset="8b587aaa-73a0-4dc8-8124-af875bb8ccdf" global_colors_info="{}"][et_pb_column type="4_4" _builder_version="4.16" _module_preset="default" global_colors_info="{}"][et_pb_text admin_label="Title" _builder_version="4.16" _module_preset="57d44031-e63c-4121-af33-69d27336dc8a" hover_enabled="0" global_colors_info="{}" sticky_enabled="0"] Thank You [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built="1" admin_label="Lorem Ipsum Dolor Sit" _builder_version="4.16" _module_preset="default" locked="off" collapsed="on" global_colors_info="{}"][et_pb_row _builder_version="4.16" _module_preset="default" global_colors_info="{}"][et_pb_column type="4_4" _builder_version="4.16" _module_preset="default" global_colors_info="{}"][et_pb_text admin_label="Title" _builder_version="4.16" _module_preset="default" header_2_text_align="center" max_width="100%" module_alignment="center" custom_margin="||10px||false|false" global_colors_info="{}"] Thank you for
- [Not Found 404](http://boracorpcdmo.com/not-found-404/) - [et_pb_section fb_built="1" admin_label="Header Title" _builder_version="4.10.7" _module_preset="b0568527-19ff-490f-b1f2-8be7d12d96d9" collapsed="on" global_colors_info="{}"][et_pb_row _builder_version="4.10.7" _module_preset="8b587aaa-73a0-4dc8-8124-af875bb8ccdf" global_colors_info="{}"][et_pb_column type="4_4" _builder_version="4.10.7" _module_preset="default" global_colors_info="{}"][et_pb_text admin_label="Title" _builder_version="4.10.7" _module_preset="57d44031-e63c-4121-af33-69d27336dc8a" global_colors_info="{}"] Oh no! Page not found. [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built="1" _builder_version="4.10.7" _module_preset="default" collapsed="off" global_colors_info="{}"][et_pb_row _builder_version="4.10.7" _module_preset="default" custom_padding="||0px||false|false" locked="off" global_colors_info="{}"][et_pb_column type="4_4" _builder_version="4.10.7" _module_preset="default" global_colors_info="{}"][et_pb_text admin_label="Title" _builder_version="4.10.7" _module_preset="default" header_2_text_align="left" max_width="100%" module_alignment="center" custom_margin="||10px||false|false" global_colors_info="{}"] Looks like you may be trying to find
- [Privacy Policy](http://boracorpcdmo.com/privacy-policy/) - [et_pb_section fb_built="1" admin_label="Header Title" _builder_version="4.18.0" _module_preset="b0568527-19ff-490f-b1f2-8be7d12d96d9" hover_enabled="0" locked="off" collapsed="off" global_colors_info="{}" background_image="http://boracdmo.com/wp-content/uploads/sites/2/2022/10/dreamstime_xxl_100760682-scaled-1.jpg" background_position="center" sticky_enabled="0"][et_pb_row _builder_version="4.16" _module_preset="8b587aaa-73a0-4dc8-8124-af875bb8ccdf" global_colors_info="{}"][et_pb_column type="4_4" _builder_version="4.16" _module_preset="default" global_colors_info="{}"][et_pb_text admin_label="Title" _builder_version="4.16" _module_preset="57d44031-e63c-4121-af33-69d27336dc8a" global_colors_info="{}"] Privacy Policy [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built="1" admin_label="Breadcrumb section" _builder_version="4.14.8" _module_preset="a827bbeb-f98d-4efb-b0e8-f296faeedfe1" custom_padding="5px||0px||false|false" global_module="242477" saved_tabs="all" collapsed="on" global_colors_info="{}"][/et_pb_section][et_pb_section fb_built="1" _builder_version="4.16" _module_preset="default" global_colors_info="{}"][et_pb_row _builder_version="4.16" _module_preset="default" collapsed="off" global_colors_info="{}"][et_pb_column type="4_4" _builder_version="4.16" _module_preset="default" global_colors_info="{}"][et_pb_text _builder_version="4.16" _module_preset="default" max_width="100%" module_alignment="center" global_colors_info="{}"] At
- [Thank you](http://boracorpcdmo.com/thank-you/) - [et_pb_section fb_built="1" admin_label="Header Title" _builder_version="4.10.7" _module_preset="b0568527-19ff-490f-b1f2-8be7d12d96d9" collapsed="off" global_colors_info="{}"][et_pb_row _builder_version="4.10.7" _module_preset="8b587aaa-73a0-4dc8-8124-af875bb8ccdf" global_colors_info="{}"][et_pb_column type="4_4" _builder_version="4.10.7" _module_preset="default" global_colors_info="{}"][et_pb_text admin_label="Title" _builder_version="4.10.7" _module_preset="57d44031-e63c-4121-af33-69d27336dc8a" global_colors_info="{}"] Thank You [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built="1" admin_label="Lorem Ipsum Dolor Sit" _builder_version="4.10.7" _module_preset="default" locked="off" collapsed="on" global_colors_info="{}"][et_pb_row _builder_version="4.10.7" _module_preset="default" global_colors_info="{}"][et_pb_column type="4_4" _builder_version="4.10.7" _module_preset="default" global_colors_info="{}"][et_pb_text admin_label="Title" _builder_version="4.10.7" _module_preset="default" header_2_text_align="center" max_width="100%" module_alignment="center" custom_margin="||10px||false|false" global_colors_info="{}"] Thank you for the opportunity to serve you
- [Sitemap](http://boracorpcdmo.com/sitemap/) - [et_pb_section fb_built="1" admin_label="Header Title" _builder_version="4.10.7" _module_preset="b0568527-19ff-490f-b1f2-8be7d12d96d9" collapsed="on" global_colors_info="{}"][et_pb_row _builder_version="4.10.7" _module_preset="8b587aaa-73a0-4dc8-8124-af875bb8ccdf" global_colors_info="{}"][et_pb_column type="4_4" _builder_version="4.10.7" _module_preset="default" global_colors_info="{}"][et_pb_text admin_label="Title" _builder_version="4.10.7" _module_preset="57d44031-e63c-4121-af33-69d27336dc8a" global_colors_info="{}"] Sitemap [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built="1" _builder_version="4.10.7" _module_preset="default" collapsed="off" global_colors_info="{}"][et_pb_row _builder_version="4.10.7" _module_preset="default" global_colors_info="{}"][et_pb_column type="4_4" _builder_version="4.10.7" _module_preset="default" global_colors_info="{}"][et_pb_text _builder_version="4.10.7" _module_preset="default" global_colors_info="{}"] Pages [/et_pb_text][et_pb_code module_class="bullet-list menu-list" _builder_version="4.14.8" _module_preset="default" hover_enabled="0" global_colors_info="{}" sticky_enabled="0"] About Bora Pharmaceuticals Accessibility Careers at Bora Culture Leadership Team
- [Element Page](http://boracorpcdmo.com/element-page/) - [et_pb_section fb_built="1" _builder_version="4.10.7" _module_preset="default" collapsed="off" global_colors_info="{}"][et_pb_row _builder_version="4.10.7" _module_preset="default" global_colors_info="{}"][et_pb_column type="4_4" _builder_version="4.10.7" _module_preset="default" global_colors_info="{}"][et_pb_text admin_label="Title" _builder_version="4.10.7" _module_preset="default" global_colors_info="{}"] H1 Heading H2 Heading H3 Heading H4 Heading H5 Heading H6 Heading [/et_pb_text][et_pb_text admin_label="Gray Text" _builder_version="4.10.7" _module_preset="a3a65f83-a427-42cf-be81-0ad16f02472f" global_colors_info="{}"]Lorem ipsum dolor sit amet, tamquam sanctus an pri. Mea cu causae verterem gloriatur, at has tollit philosophia vituperatoribus. Eu magna

## My Templates

- [Elementor Loop Item #987498779](http://boracorpcdmo.com/?elementor_library=elementor-loop-item)
- [External Link Confirmation](http://boracorpcdmo.com/?elementor_library=external-link-confirmation) - You’re leaving our site You are being redirected to BoraBiologics.com Proceed Cancel
- [Header EN](http://boracorpcdmo.com/?elementor_library=header-en-3) - Contact us
- [CTO](http://boracorpcdmo.com/?elementor_library=cto) - Making Success More Certain As a future focused CDMO, we know better than most that our own success is shaped by our partners victories. At Bora Pharmaceuticals, we see it as our mission, our duty, and our responsibility to make our mutual success more certain. Speak with an Expert
- [Elementor Single Page #987500929](http://boracorpcdmo.com/?elementor_library=elementor-single-page-987500929) - Home
- [Footer EN](http://boracorpcdmo.com/?elementor_library=footer-en) - Bora Contact Investors: +886-2-2790-1555 CDMO Inquires: Toll Free: 1-844-626-7846 Address 6F., No. 2, Aly. 36, Ln. 26, Ruiguang Rd., Neihu District, Taipei City, 114 Taiwan Youtube Linkedin Quick Links Copyright © 2025 Bora Pharmaceuticals. Developed by Engage.
- [Bora Corp Export](http://boracorpcdmo.com/?elementor_library=bora-corp-export)
- [Single Post EN](http://boracorpcdmo.com/?elementor_library=single-post-en) - Home
- [Loop With Image No Category](http://boracorpcdmo.com/?elementor_library=loop-with-image-no-category)
- [Home Loop - No Image](http://boracorpcdmo.com/?elementor_library=home-loop-no-image)
- [Archive Page](http://boracorpcdmo.com/?elementor_library=archive-page) - Home [fe_widget]
- [Loop With Image and Category](http://boracorpcdmo.com/?elementor_library=loop-with-image-and-category)
- [Imported Kit](http://boracorpcdmo.com/?elementor_library=imported-kit)
- [Header](http://boracorpcdmo.com/?elementor_library=header-en) - Home Dosage Forms Oral Solid Dose Semi-Solids Liquids Nasal Sprays Ophthalmic Sterile Injectables Manufacturing & Packaging Small Scale and Pilot Scale-Up and Commercial Packaging & Serialization Development & Analytical Services Formulation Development Analytical Development Analytical Testing Stability Testing and Storage Biologics Cell Line & Process Development Analytical & Formulation Development Manufacturing Quality Management Project Management
- [Footer](http://boracorpcdmo.com/?elementor_library=elementor-footer-987500021) - Contact Contact Us Quick Links Stay Connected Get the industry insights you care about. Join 3000+ subscribers and receive Bora resources and updates by email.
- [Elementor Search Results #987499552](http://boracorpcdmo.com/?elementor_library=elementor-search-results-987499552)
- [Error 404](http://boracorpcdmo.com/?elementor_library=error-404) - 404 No Results Found The page you requested could not be found. Try refining your search, or use the navigation above to locate the post. Go to the Homepage
- [Post Archive](http://boracorpcdmo.com/?elementor_library=elementor-archive-987498776)
- [Elementor Single Post #987498982](http://boracorpcdmo.com/?elementor_library=elementor-single-post-987498982) - Please share this content with others who may benefit from it. LinkedIn You may also be interested
- [Single Page](http://boracorpcdmo.com/?elementor_library=elementor-single-page-987500025)
- [Section Bottom New](http://boracorpcdmo.com/?elementor_library=section-bottom-new) - Making Success More Certain As a future focused CDMO, we know better than most that our own success is shaped by our partners victories. At Bora Pharmaceuticals, we see it as our mission, our duty, and our responsibility to make our mutual success more certain. Speak with an Expert
- [single-page-bottom](http://boracorpcdmo.com/?elementor_library=single-page-bottom) - Trusted Partner Our team is here to discuss how you can gain competitive advantage by leveraging Bora’s rich and diverse manufacturing and packaging expertise towards your commercial success. Contact a Bora Expert
- [leadership](http://boracorpcdmo.com/?elementor_library=leadership) - Bobby Sheng Group CEO & Chairman Simon Chen Vice President, R&D Alice Wang CFO, HQ & APAC Nick Liu President, TWi Pharmaceuticals J.D. Mowery President, CDMO Business Tom Chang President, Bora Pharmaceutical Laboratories Inc. Stefan Schnydrig Senior VP & Chief Human Resources Officer Goff Baker VP of Quality Frank Chen VP of IT Jason Foss
- [Homepage](http://boracorpcdmo.com/?elementor_library=homepage) - Unlocking Breakthroughs. Accelerating Progress. Work With Us We partner with innovative and leading pharmaceutical companies to enable the development, manufacture and packaging of small molecule drug products and large molecule drug substance. Our Mission “Contributing to Better Health All Over the World” is Bora’s Mission. We are the driving force to help people improve their
- [Header EN](http://boracorpcdmo.com/?elementor_library=header-en-2) - Technology Transfer Subscribe Subscribe to our weekly newsletter for updates and news Email Sign Up Subscribe Subscribe to our weekly newsletter for updates and news [wpml_language_selector_widget]
- [files](http://boracorpcdmo.com/?elementor_library=files) - 2023 ESG Report 2022 ESG Report 2021 ESG Report
- [Footer Success](http://boracorpcdmo.com/?elementor_library=footer-success) - Making Success More Certain Our team is here to discuss how we can become a trusted partner to help bring your breakthrough drug successfully to market.
- [Default Kit](http://boracorpcdmo.com/?elementor_library=default-kit)

## Categories

- [Uncategorized](http://boracorpcdmo.com/category/uncategorized/)
- [Articles](http://boracorpcdmo.com/category/articles/)
- [News and Events](http://boracorpcdmo.com/category/news-and-events/)
- [Press Mentions](http://boracorpcdmo.com/category/news-and-events/borapressmentions/)

## Tags

- [Biologics](http://boracorpcdmo.com/tag/biologics/)
- [Careers](http://boracorpcdmo.com/tag/careers/)
- [CDMO](http://boracorpcdmo.com/tag/cdmo/)
- [Contract Manufacturer](http://boracorpcdmo.com/tag/contract-manufacturer/)
- [Drug Development](http://boracorpcdmo.com/tag/drug-development/)
- [Manufacturing Expansion](http://boracorpcdmo.com/tag/manufacturing-expansion/)
- [Technology Transfer](http://boracorpcdmo.com/tag/technology-transfer/)
- [Topical](http://boracorpcdmo.com/tag/topical/)